|Printable version||E-mail this to a friend|
Cancer Research UK - Precision medicine trial first of its kind to show benefit to patients
A clinical trial for types of advanced cancer is the first of its kind to show that precision medicine – or tailoring treatment for individual people – can slow down the time it takes for a tumour to grow back, according to research presented at the Molecular Analysis for Personalised Therapy (MAP) conference(link is external), last week.
Results from the trial, which took place at the Gustave Roussy Cancer Campus(link is external) in Paris, found that 199 out of 1110 patients with advanced cancer, who had their genes mapped and their treatment tailored, had around 30 per cent longer before their cancer started growing again compared to any of the previous therapies the patients had tried. This ranged from between five and 32 months.
This trial involved patients who had no other treatment options left and who had already tried three or more cancer therapies. The team found potential faulty molecules to target for 411 of these patients and experimental drugs to hit the targets for 199 of these patients.
The patients on this trial had diverse types of advanced cancer including lung, breast, head and neck, prostate, bladder, bowel and stomach cancer.
The MAP conference is a joint initiative between Cancer Research UK, UNICANCER and ESMO.
Professor Jean Charles Soria, principal investigator of the trial from the Gustave Roussy Cancer Campus, said: “This is the first precision medicine trial to show that analysing a person’s DNA improves treatment options for patients with late stage cancer. And these results are particularly exciting because in some cases we were testing experimental drugs, and found that we could slow down the growth of tumours in around one in five patients with advanced cancer.”
Dr Christophe Massard, head of the early drug development multidisciplinary committee at Gustave Roussy, said: “The great thing about this is that it’s not just for one type of cancer - patients with many different types of cancer could benefit from this in the future.”
Dr Rowena Sharpe, head of precision medicine at Cancer Research UK, said: “This is an exciting time for precision medicine and personalised treatment. It’s fantastic to see continued effort going into this area and it’s important that we make the most of the data that we already have. The MAP meeting brings together expertise from across the globe to find the best ways to improve precision medicine programmes for cancer patients.”
For media enquiries please contact the Cancer Research UK press office on +44 203 469 8300 or, out-of-hours, the duty press officer on +44 7050 264 059.
Notes to Editor
The clinical trial is called MOSCATO 01
Latest News from
Cancer Research UK - Lifetime weight gain linked to oesophageal and stomach cancers16/02/2017 15:35:00
People who are overweight in their twenties and become obese later in life may be three times more likely to develop cancer of either the oesophagus (food pipe) or upper stomach, according to a study published in the British Journal of Cancer on Wednesday.
Age UK - 'Borrowed time' to save social care system from collapse16/02/2017 11:35:00
A new report from Age UK has concluded that we are living on borrowed time to save the social care system for older people.
Cancer Research UK - NHS cancer treatment target in England missed for third consecutive year14/02/2017 12:35:00
The ’62 day’ waiting time target for cancer patients in England has been missed again, marking 3 years since the target was last met.
Cancer Research UK - More support needed for GPs to make best use of cancer preventing drugs14/02/2017 10:35:00
A new Cancer Research UK report reveals that GPs want more support when offering drugs that lower the risk of certain cancers.